Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Scientific Officer | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 158,844 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 4,000 · Balance 166,844 Row 2 · 2026-09-08 · Sale · Disposed 8,000 · Balance 158,844 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28 | Direct | 78,987 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 4,000 · Balance 78,987 F3: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-019456 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,582 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,145 | $8.50 | $9,732.50 |
DisclosureSEC source: 0000950170-23-072753 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,582 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 238 | $8.22 | $1,956.36 |
DisclosureSEC source: 0000950170-23-071988 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,727 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 01:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,068 | $7.81 | $8,341.08 |
DisclosureSEC source: 0000950170-23-070142 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,965 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:17 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 238 | $12.94 | $3,079.72 |
DisclosureSEC source: 0000950170-23-029160 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,033 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 176 | $13.11 | $2,307.36 |
DisclosureSEC source: 0000950170-23-027984 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,271 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · derivative · entry 6 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,593 Underlying: Common Stock · 100 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 100 | $12.40 | $1,240.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · nonDerivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,447 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 100 | $4.30 | $430.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,900 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · derivative · entry 5 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,693 Underlying: Common Stock · 11,900 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 11,900 | $12.31 | $146,489.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,447 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 11,900 | $4.30 | $51,170.00 |
DisclosureSEC source: 0000950170-23-027063 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:51 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 239 | $8.76 | $2,093.64 |
DisclosureSEC source: 0000899243-23-013364 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,447 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 193 | $8.78 | $1,694.54 |
DisclosureSEC source: 0000950170-23-022557 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,686 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:32 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 238 | $10.71 | $2,548.98 |
DisclosureSEC source: 0000950170-23-013701 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,879 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 22:23 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 176 | $10.22 | $1,798.72 |
DisclosureSEC source: 0000899243-23-011292 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,117 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| March 20, 2023 Filed Mar 27, 2023 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 238 | $11.32 | $2,694.16 |
DisclosureSEC source: 0000899243-23-009716 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,293 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:52 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0000899243-23-005729 · doc4.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2033-02-16 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:52 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 38,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005729 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,531 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-22-037126 · doc4.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,593 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,000 | $13.30 | $53,200.00 |
DisclosureSEC source: 0000899243-22-037126 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.96 to $13.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-22-037126 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-22-032236 · doc4.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,593 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,000 | $12.40 | $49,600.00 |
DisclosureSEC source: 0000899243-22-032236 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-22-032236 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 21:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,385 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-22-028132 · doc4.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,593 Underlying: Common Stock · 1,385 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 21:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,385 | $15.01 | $20,788.85 |
DisclosureSEC source: 0000899243-22-028132 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 21:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 1,385 | $4.30 | $5,955.50 |
DisclosureSEC source: 0000899243-22-028132 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 21:44 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-22-026737 · doc4.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,978 Underlying: Common Stock · 8,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 21:44 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $14.51 | $116,080.00 |
DisclosureSEC source: 0000899243-22-026737 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.76. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 21:44 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 8,000 | $4.30 | $34,400.00 |
DisclosureSEC source: 0000899243-22-026737 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 22:10 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 1,620 | $10.90 | $17,658.00 |
DisclosureSEC source: 0000899243-22-025082 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:55 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 57,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-22-006427 · doc4.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2032-02-10 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:55 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 28,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006427 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,411 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-040764 · doc4.xml · derivative · entry 5 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 400 | $23.61 | $9,444.00 |
DisclosureSEC source: 0000899243-21-040764 · doc4.xml · nonDerivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.96. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 204 | $22.40 | $4,569.60 |
DisclosureSEC source: 0000899243-21-040764 · doc4.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,311 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.73. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,396 | $21.10 | $71,655.60 |
DisclosureSEC source: 0000899243-21-040764 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,515 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-21-040764 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-036782 · doc4.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 800 | $25.20 | $20,160.00 |
DisclosureSEC source: 0000899243-21-036782 · doc4.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.95 to $25.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,200 | $24.34 | $77,888.00 |
DisclosureSEC source: 0000899243-21-036782 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,711 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.92 to $24.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-21-036782 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,137 | $28.07 | $31,915.59 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 2,863 | $27.50 | $78,732.50 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,048 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,137 | $28.07 | $31,915.59 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 2,863 | $27.50 | $78,732.50 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,048 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.